The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
During the first 6 months of glatiramer acetate therapy in 82 consecutive patients with multiple sclerosis, in only 6% frequency of pre-existing headaches increased by more than 50%. This is less than the headache aggravation reported in an earlier study in up to 35% of patients during the first 6 months on interferon beta.
Pöllmann
Walter
W
Marianne-Strauss-Klinik, Berg, Germany. Walter.Poellmann@ms-klinik.info
Erasmus
Lutz-Peter
LP
Feneberg
Wolfgang
W
Straube
Andreas
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D005260:Female; D000068717:Glatiramer Acetate; D006261:Headache / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta